ENTREPRENEURSHIP ARTICLES
-
![Debt and loan problem, financial mistake, bankruptcy, stress-GettyImages-2257060489]( "Execution Debt In Early Drug Discovery: The Hidden Risk That Undermines Promising Biology")
Execution Debt In Early Drug Discovery: The Hidden Risk That Undermines Promising BiologyUnderstanding how execution debt forms, how it compounds, and how to prevent it is central to building durable discovery programs.
-
![GettyImages-2246207235]( "Annual Reflections And Predictions From The Editors' Roundtable")
Annual Reflections And Predictions From The Editors' RoundtableUnderstanding the full scope of the life science industry has never been more critical. Ray Dogum, Chief Editor of Drug Discovery Online, joins the Life Science Connect Editors’ Roundtable on a special episode of Better Biopharma podcast.
-
![Stop Fentanyl-GettyImages-2198578451]( "The Unlikely Weapon Against Fentanyl: Your Immune System")
The Unlikely Weapon Against Fentanyl: Your Immune SystemARMR Sciences Inc. has developed a vaccine designed with a novel adjuvant, dmLT, to neutralize fentanyl in the bloodstream before it reaches the central nervous system and binds to μ-opioid receptors (MORs).
-
![advancement innovation-GettyImages-2218939025]( "2025's Top 5 Drug Discovery Highlights And How To Stay Ahead In 2026")
2025's Top 5 Drug Discovery Highlights And How To Stay Ahead In 2026Drug Discovery Online's 2025 Top 5 most consequential shifts affecting this rapidly evolving field, including NAMs, AI, Individualized Therapies, Innovating China, and Early-stage Funding Volatility.
-
![Cancer detection-GettyImages-1477214805]( "GO‑4 Drug Combo Offers New Hope for Treating Late-Stage BRCA/PALB2-Mutated Cancers")
GO‑4 Drug Combo Offers New Hope for Treating Late-Stage BRCA/PALB2-Mutated CancersGeneral Oncology’s GO‑4 is an investigational product combining melphalan, BCNU, hydroxocobalamin, and ascorbic acid. The company's CEO, Jeff Glazier shared how the combo is designed to shut down DNA repair and resensitize hard‑to‑treat tumors to chemotherapy for patients with advanced pancreatic or breast cancer.
-
![GettyImages-2207965610]( "OpenFold3 Released: Redefining The Limits Of Protein Prediction Models")
OpenFold3 Released: Redefining The Limits Of Protein Prediction ModelsOpenFold3, a biomolecular structure prediction model based on AlphaFold3 was recently released by the OpenFold Consortium, a non-profit AI R&D organization.
-
![BIO 2025 - Exhibition Floor]( "Five Takeaways from BIO 2025 and Why You Should Stay Tuned")
Five Takeaways from BIO 2025 and Why You Should Stay TunedNew chief editor of Drug Discovery Online shares insights from BIO 2025’s global biotech gathering and spotlights the impacts to early-stage drug research.
-
![FDA headquarter iStock-1213293784]( "FDA Seeks Comment On ICH Q9(R1) Quality Risk Management")
FDA Seeks Comment On ICH Q9(R1) Quality Risk ManagementICH has revised Q9 Quality Risk Management, providing principles and tools that can be applied throughout the product life cycle of drug substances, drug products, biological, and biotech products. The FDA, a founding member of the ICH, plays a major role in the development of ICH guidelines, which FDA then adopts and issues as guidance to industry.
-
![Motivational and inspirational words GettyImages-1175456827]( "How To Set Up An Effective Quality Risk Management Program")
How To Set Up An Effective Quality Risk Management ProgramThe author of this article has taught courses on quality risk management (QRM) and its implementation as well as seen it in action in many companies. This article, Part 1 of a 2-part series, shares some of his observations and lessons learned in setting up an effective QRM program.
-
![Risk Management in Web Clinical Trials]( "Risk Management in Web Clinical Trials")
Risk Management in Web Clinical Trials Have you thought about risk management in your Web clinical trial? What are the risks?...
ENTREPRENEURSHIP VIDEOS
Rahul Kakkar explains his transition from architecture student to MD and how he maintains a cardiology practice while leading Tome Biosciences, which he co-founded.
As biotech capital markets continue to restrict access to funding for emerging biopharmas, you might be surprised by how many federal dollars get left on the negotiating table. To that end, James Thomas Coates, Ph.D. and his team at Decisive Point have carved out a niche in the venture capital space.
Ben Zeskind launched his biotech, Immuneering, in the throes of the Great Recession. The company earned a $20 million series A round to fund the development of its pipeline at the outset of the COVID-19 pandemic. Along the way, it bootstrapped its way from bioinformatics company to fledgling biopharma. On this episode of The Business Of Biotech, Zeskind shares his experience-based wisdom on finding funding in volatile times.